Phase 2 STRIVE Clinical Trial of Rezafungin for the Treatment of Candidemia and/or Invasive

Candidemia: Results Stratified by Baseline Renal Function

### RESULTS

<table>
<thead>
<tr>
<th>Parameter</th>
<th>N=42</th>
<th>N=23</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rezafungin AUC (µg*hr/mL)</td>
<td>28 (67.1)</td>
<td>24 (51.0)</td>
</tr>
</tbody>
</table>

### DISCUSSION

- The study was conducted on patients with baseline renal function ranging from normal to severe impairment.
- Rezafungin AUC values were found to be significantly lower in patients with severe renal impairment.
- This suggests that renal function plays a critical role in determining the exposure and efficacy of rezafungin.

### CONCLUSIONS

- The results indicate that rezafungin is effective even in patients with severe renal impairment.
- Further studies are needed to confirm these findings and optimize dosing regimens.

### REFERENCES
